Considering that tumor cells can evade T-cell immunity through interaction with PD-L1/PD-1, various immune checkpoint inhibitors with monoclonal antibodies blocking the interaction of PD-L1/PD-1 that consequentially inhibit tumor cell evasion from T-cells have been developed [25]. Here, PDCD1 is linked to neoplasm.